British-Swedish drugmaker AstraZeneca said that its Covid-19 vaccine Vaxzevria carries a small extra risk of rare blood clots with low platelets after the first dose, but no extra risk after the second shot.
A study led and funded by the drugmaker which was published in the Lancet medical journal found that the estimated rate of thrombosis with thrombocytopenia (TTS) after the first dose was 8.1 per million in those vaccinated.
Vaxzevria is made in India by Pune based Serum Institute of India (SII) and marketed as Covishield.
The vaccine which is co-developed by the University of Oxford, the AstraZeneca vaccine